EGFR and non-small cell lung carcinoma: Similarly, in a phase Ib clinical trial of Osimertinib (a third-generation EGFR TKI) combined with the PD-L1 monoclonal antibody durvalumab for the therapy of NSCLC patients with EGFR mutations, the objective remission rate in the Osimertinib monotherapy group is 80%, but only 64% in the combination therapy group.